Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1232859 | 0.89 | KDM4E (0.38) | KDM4EALDH1A1 | |
| SCHEMBL8903874 | 0.87 | ALDH1A1 (0.37) | KDM4EALDH1A1 | |
| SCHEMBL4752145 | 0.87 | ALDH1A1 (0.37) | KDM4EALDH1A1 | |
| SCHEMBL6900407 | 0.87 | ALDH1A1 (0.37) | KDM4EALDH1A1 | |
| SCHEMBL6900404 | 0.87 | ALDH1A1 (0.37) | KDM4EALDH1A1 | |
| SCHEMBL9517109 | 0.81 | — | — | |
| SCHEMBL595872 | 0.81 | ALDH1A1 (0.44) | KDM4EALDH1A1 | |
| SCHEMBL11072218 | 0.81 | KDM4E (0.30) | KDM4EALDH1A1 | |
| SCHEMBL11030411 | 0.78 | KDM4E (0.31) | KDM4EALDH1A1 | |
| SCHEMBL7124125 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8198296-B2 | Sub-type selective azabicycloalkane derivatives | TARGACEPT, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263629-A1 | AMIDES OF DIAZABICYCLOOCTANES AND USES THEREOF | TARGACEPT, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2364150-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | Targacept Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2344496-A1 | AMIDES OF DIAZABICYCLOOCTANES AND USES THEREOF | Targacept Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110071180-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2257549-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES | Targacept Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2010056622-A1 | TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010028011-A1 | AMIDES OF DIAZABICYCLONONANES AND USES THEREOF | TARGACEPT, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010028033-A1 | AMIDES OF DIAZABICYCLOOCTANES AND USES THEREOF | TARGACEPT, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| EP-2139857-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | Targacept Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2009111550-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES | TARGACEPT, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2008121686-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008112734-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | CHRNA7, CHRNA2, CHRNA4 | KDM4E 3190/4885ALDH1A1 1381/4885 |
| US-20110071180-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | CHRNA7, CHRNA2, CHRNA5 | KDM4E 2513/4885ALDH1A1 1201/4885 |
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | CHRNA10, CHRNA2, CHRNE | KDM4E 2876/4885ALDH1A1 1528/4885 |
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | CHRNB2, CHRNB4, CHRNA4 | KDM4E 1204/4885ALDH1A1 991/4885 |
| US-20110263629-A1 | AMIDES OF DIAZABICYCLOOCTANES AND USES THEREOF | CHRNA2, CHRNA10, CHRNA5 | KDM4E 2399/4885ALDH1A1 1530/4885 |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | CHRNA7, CHRNA4, CHRNA2 | KDM4E 3101/4885ALDH1A1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.